AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXR
  4. [Form 4] Daxor Corporation Insider Trading Activity

[Form 4] Daxor Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Daxor Corporation (DXR) filed a Form 4 on 26-Jun-2025 disclosing that director Caleb DesRosiers received 2,500 non-qualified stock options on 24-Jun-2025. The options carry an exercise price of $9.29 and expire on 24-Jun-2030. Vesting occurs in three installments: 833 options on 24-Jun-2025, 833 on 24-Jun-2026 and 834 on 24-Jun-2027. Following the grant, DesRosiers beneficially owns 2,500 derivative securities directly.

The award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. No common-stock purchases or sales were reported, making this a routine compensation-related disclosure rather than a signal of insider sentiment.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small routine option grant to director; neutral effect on DXR valuation and insider sentiment.

The filing reveals a straightforward compensation grant: 2,500 options at $9.29, expiring in 2030 and vesting over three years. Because no common shares were bought or sold, the transaction does not change insider economic exposure today. The volume is modest relative to DXR’s public float, and the exercise price aligns with contemporaneous market levels, limiting immediate dilution concerns. Conditional SEC approval of the plan amendment introduces a procedural step but is unlikely to derail the grant. Overall, the disclosure appears neutral for investors.

TL;DR: Governance-compliant option grant; contingent on plan amendment; neutral impact.

Granting stock options to non-employee directors is a standard governance practice to align interests with shareholders. The three-year vesting schedule encourages medium-term oversight, while the term through 2030 is reasonable. The contingency regarding SEC approval reflects procedural caution as the company amends its 2020 Incentive Compensation Plan. Provided approval is obtained, the grant fits typical board-compensation norms and carries no red flags.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DesRosiers Caleb
(Last) (First) (Middle)
109 MECO LANE
(Street)
OAK RIDGE, TN 37830
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options (right to buy) $9.29 06/24/2025(1) A 2,500 (2) 06/24/2030 Common Stock 2,500 $0 2,500 D
Explanation of Responses:
1. Stock options granted on June 24, 2025 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan")
2. The stock options will vest in three (3) installments - June 24, 2025 (833); June 24, 2026 (833); June 24, 2027 (834)
/s/ Caleb DesRosiers 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transaction did Daxor (DXR) report on Form 4 dated 26-Jun-2025?

The filing shows a grant of 2,500 stock options to director Caleb DesRosiers executed on 24-Jun-2025.

What is the exercise price of the options granted to Caleb DesRosiers?

The options have an exercise price of $9.29 per share.

When do the Daxor options vest?

They vest in three tranches: 24-Jun-2025 (833), 24-Jun-2026 (833) and 24-Jun-2027 (834).

When do the options expire?

The options expire on 24-Jun-2030.

Is the option grant subject to any conditions?

Yes. It is contingent on SEC approval of an amendment to Daxor’s 2020 Incentive Compensation Plan.

Did the filing report any purchase or sale of common stock?

No. Only the derivative option grant was disclosed; no non-derivative share transactions were reported.
Stock DXR logo
DAXOR CORP

NASDAQ:DXR

DXR Rankings

#5225 Ranked by Market Cap
N/A Ranked by Dividends

DXR Latest News

Aug 12, 2025
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Aug 7, 2025
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System
Jul 22, 2025
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
May 14, 2025
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
May 13, 2025
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

DXR Latest SEC Filings

Aug 7, 2025
[8-K] Daxor Corporation Reports Material Event
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 24, 2025
[N-CEN/A] Daxor Corporation SEC Filing
Jul 1, 2025
[8-K] Daxor Corporation Reports Material Event
Jun 26, 2025
[Form 4] Daxor Corporation Insider Trading Activity

DXR Stock Data

49.72M
2.14M
56.9%
1.96%
0.22%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
United States
NEW YORK